Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Silvia Chiara Formenti, Sandra Demaria · JNCI Journal of the National Cancer Institute · 2013
The therapeutic application of ionizing radiation has been largely based on its cytocidal power combined with the ability to selectively target tumors. Radiotherapy effects on survival of cancer patients are generally interpreted as the consequence of improved local control of the tumor, directly decreasing systemic spread. Experimental data from multiple cancer models have provided sufficient evidence to propose a paradigm shift, whereby some of the effects of ionizing radiation are recognized as contributing to systemic antitumor immunity. Recent examples of objective responses achieved by adding radiotherapy to immunotherapy in metastatic cancer patients support this view. Therefore, the traditional palliative role of radiotherapy in metastatic disease is evolving into that of a powerful adjuvant for immunotherapy. This combination strategy adds to the current anticancer arsenal and offers opportunities to harness the immune system to extend survival, even among metastatic and heavily pretreated cancer patients. We briefly summarize key evidence supporting the role of radiotherapy as an immune adjuvant. A critical appraisal of the current status of knowledge must include potential immunosuppressive effects of radiation that can hamper its capacity to convert the irradiated tumor into an in situ, individualized vaccine. Moreover, we discuss some of the current challenges to translate this knowledge to the clinic as more trials testing radiation with different immunotherapies are proposed.
Cited by 1,053 works. doi:10.1093/jnci/djs629 Open-access PDF
Authors
References
- Hallmarks of Cancer: The Next Generation
- The blockade of immune checkpoints in cancer immunotherapy
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- Cancer immunoediting: from immunosurveillance to tumor escape
- Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials
- The Three Es of Cancer Immunoediting